These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 26282726)

  • 1. Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial).
    Nagarakanti R; Wallentin L; Noack H; Brueckmann M; Reilly P; Clemens A; Connolly SJ; Yusuf S; Ezekowitz MD
    Am J Cardiol; 2015 Oct; 116(8):1204-9. PubMed ID: 26282726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
    Chevalier J; Giroud M; de Pouvourville G
    Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
    Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Kent AP; Pogue J; Spahr J; Clemens A; Noack H; Diener HC; Wallentin L; Yusuf S; Connolly SJ
    Europace; 2016 Jul; 18(7):973-8. PubMed ID: 26944733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
    Ezekowitz MD; Wallentin L; Connolly SJ; Parekh A; Chernick MR; Pogue J; Aikens TH; Yang S; Reilly PA; Lip GY; Yusuf S;
    Circulation; 2010 Nov; 122(22):2246-53. PubMed ID: 21147728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial.
    Brambatti M; Darius H; Oldgren J; Clemens A; Noack HH; Brueckmann M; Yusuf S; Wallentin L; Ezekowitz MD; Connolly SJ; Healey JS
    Int J Cardiol; 2015 Oct; 196():127-31. PubMed ID: 26093161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
    Lip GY; Clemens A; Noack H; Ferreira J; Connolly SJ; Yusuf S
    Thromb Haemost; 2014 May; 111(5):933-42. PubMed ID: 24326736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
    Lee KH; Park HW; Lee N; Hyun DY; Won J; Oh SS; Park HJ; Kim Y; Cho JY; Kim MC; Sim DS; Yoon HJ; Yoon NS; Kim KH; Hong YJ; Kim JH; Ahn Y; Jeong MH; Park JC; Cho JG
    Europace; 2017 Dec; 19(suppl_4):iv1-iv9. PubMed ID: 29220421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
    Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
    Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.
    Gorst-Rasmussen A; Lip GY; Bjerregaard Larsen T
    Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1236-1244. PubMed ID: 27229855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
    Ezekowitz MD; Nagarakanti R; Noack H; Brueckmann M; Litherland C; Jacobs M; Clemens A; Reilly PA; Connolly SJ; Yusuf S; Wallentin L
    Circulation; 2016 Aug; 134(8):589-98. PubMed ID: 27496855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
    Wallentin L; Yusuf S; Ezekowitz MD; Alings M; Flather M; Franzosi MG; Pais P; Dans A; Eikelboom J; Oldgren J; Pogue J; Reilly PA; Yang S; Connolly SJ;
    Lancet; 2010 Sep; 376(9745):975-83. PubMed ID: 20801496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
    Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Reilly PA; Lehr T; Haertter S; Connolly SJ; Yusuf S; Eikelboom JW; Ezekowitz MD; Nehmiz G; Wang S; Wallentin L;
    J Am Coll Cardiol; 2014 Feb; 63(4):321-8. PubMed ID: 24076487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dabigatran according to age in atrial fibrillation.
    Lauw MN; Eikelboom JW; Coppens M; Wallentin L; Yusuf S; Ezekowitz M; Oldgren J; Nakamya J; Wang J; Connolly SJ
    Heart; 2017 Jul; 103(13):1015-1023. PubMed ID: 28213368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
    Seeger JD; Bykov K; Bartels DB; Huybrechts K; Zint K; Schneeweiss S
    Thromb Haemost; 2015 Nov; 114(6):1277-89. PubMed ID: 26446507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
    Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
    Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Connolly SJ; Wallentin L; Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Pogue J; Alings M; Amerena JV; Avezum A; Baumgartner I; Budaj AJ; Chen JH; Dans AL; Darius H; Di Pasquale G; Ferreira J; Flaker GC; Flather MD; Franzosi MG; Golitsyn SP; Halon DA; Heidbuchel H; Hohnloser SH; Huber K; Jansky P; Kamensky G; Keltai M; Kim SS; Lau CP; Le Heuzey JY; Lewis BS; Liu L; Nanas J; Omar R; Pais P; Pedersen KE; Piegas LS; Raev D; Smith PJ; Talajic M; Tan RS; Tanomsup S; Toivonen L; Vinereanu D; Xavier D; Zhu J; Wang SQ; Duffy CO; Themeles E; Yusuf S
    Circulation; 2013 Jul; 128(3):237-43. PubMed ID: 23770747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.
    Diener HC; Connolly SJ; Ezekowitz MD; Wallentin L; Reilly PA; Yang S; Xavier D; Di Pasquale G; Yusuf S;
    Lancet Neurol; 2010 Dec; 9(12):1157-1163. PubMed ID: 21059484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.